Argenx (ARGX) announced the U.S. FDA approved a label expansion for Vyvgart and Vyvgart Hytrulo for the treatment of adult patients with generalized myasthenia gravis. The approved supplemental Biologics License Application expands Vyvgart’s indication to include all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
- Argenx price target raised to $1,135 from $1,120 at Guggenheim
- Argenx price target raised to $1,260 from $1,247 at Wells Fargo
- Argenx price target lowered to $1,222 from $1,227 at Stifel
- Argenx Posts 63% Q1 Sales Surge as New CEO Steers Expansion of Autoimmune Portfolio